Invivyd Reports Positive Phase 3 LIBERTY Data for VYD2311
NEW HAVEN, Conn. — September 29, 202 Invivyd announced topline results from the Phase 3 LIBERTY study evaluating VYD2311,...
antiviral therapy
Advertisement
Mirum Advances Brelovitug in Phase 3 HDV Trial
Foster City, California, U.S., September 28, 2026 Mirum Pharmaceuticals has announced a major clinical-development milestone for brelovitug, an investigational...
Gilead and PAHO Expand Lenacapavir HIV Prevention Access
FOSTER CITY, Calif. — September 17, 2026 Gilead Sciences, Inc. announced a new agreement with the Pan American Health...
Leyden Labs Advances RIG-101 Toward Phase 2 in Asthma
LEIDEN, Netherlands — September 9, 2026 Leyden Laboratories B.V. announced positive Phase 1 results for RIG-101, supporting advancement of...
AstraZeneca, Daiichi Sankyo Win EU Approval for Enhertu
CAMBRIDGE, UK, Sept. 1, 2026 AstraZeneca and Daiichi Sankyo announced that the European Commission has approved Enhertu (trastuzumab deruxtecan)...
Advertisements
Enliven to Present Clinical Data at SOHO 2026 Meeting
SAN FRANCISCO, California, Sept. 2, 2026 Enliven Therapeutics announced plans to present new clinical and preclinical data from its...
UCB Agreement Targets Medicine Costs and U.S. Manufacturing
BRUSSELS, Belgium and ATLANTA, Georgia, Aug. 31, 2026 UCB has reached an agreement with the U.S. government aimed at...
TTX-MC138 Shows Survival Benefit in Breast Cancer
BOSTON, Aug. 31, 2026 TransCode Therapeutics announced the publication of new peer-reviewed research reporting a survival benefit for TTX-MC138...
RedHill Advances Opaganib for Ebola Outbreak Response
Raleigh, North Carolina, August 31, 2026 RedHill Biopharma Ltd. announced an update on the emergency development of opaganib as...
Summit Therapeutics Gains China Approval for Ivonescimab
Miami, Florida, August 12, 2026 Summit Therapeutics announced that its partner Akeso Inc. received marketing authorization from China’s National...
Advertisement
